Who are Suprax's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefixime.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Suprax — Competitive Intelligence Brief

Suprax (CEFIXIME) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cefixime. Area: Infectious Disease.

marketed cefixime 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Suprax (CEFIXIME). Suprax works by inhibiting the bacterial enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, disrupting bacterial cell wall synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Suprax TARGET	CEFIXIME		marketed	cefixime	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	1989-01-01

Recent regulatory actions (last 90 days)

2026-03-23 — Suprax · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-12-14 — Suprax · 9233112 · Formulation · US

Sponsor landscape (cefixime class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Suprax — Competitive Intelligence Brief. https://druglandscape.com/ci/cefixime. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab